• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by IM Cannabis Corp.

    7/31/25 5:27:14 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email
    6-K 1 zk2533508.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of July 2025 (Report No. 4).
     
    Commission File Number: 001-40065

    IM Cannabis Corp.
    (Exact Name of Registrant as Specified in Charter)

    Kibbutz Glil Yam, Central District, Israel 4690500
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒  Form 40-F ☐
     


    CONTENTS

    Private Placement Offering
     
    On July 30, 2025, IM Cannabis Corp. (the “Company”) entered into subscription agreements (the “Subscription Agreements”) for a private placement financing with certain investors (the “Offering”). Under the Subscription Agreements, the investors have agreed to purchase an aggregate of 2,050,000 units (each a “Unit”, and collectively, the “Units”) at a purchase price of C$2.74 per Unit. Each Unit consists of one common share of the Company, no par value per share (the “Common Shares”), or one common share pre-funded warrant in lieu thereof (the “Pre-Funded Warrants”), and one common share purchase warrant (the “Warrants”).
     
    The Offering amount and Unit price were calculated based on the official exchange rate as of July 21, 2025, of 1 USD = 1.3713 CAD (USD/ILS = 3.3550; CAD/ILS = 2.4465) as published on the website of the Bank of Israel (the “Exchange Rate”).
     
    Each Warrant entitles its holder to purchase one Common Share (each, a “Warrant Share”) at an exercise price of C$3.43 per Warrant Share, became exercisable immediately upon issuance and for a period of sixty (60) months from its issuance. If the Warrants are not exercised by the applicable expiry date, the Warrants will expire and be of no further force or effect. The Warrants and the Warrant Shares may not be traded for a period of four (4) months, unless permitted under applicable securities legislation.
     
    Each Pre-Funded Warrant entitles its holder to purchase one Common Share (each, a “Pre-Funded Share”) at a price of C$0.00001 per Pre-Funded Share, became exercisable immediately upon issuance and may be exercised at any time until exercised in full. The Pre-Funded Warrants and the Pre-Funded Warrant Shares may not be traded for a period of four (4) months, unless permitted under applicable securities legislation.
     
    The Offering resulted in gross proceeds to the Company of C$5,622,522, which the Company intends to use for general working capital, repayment of existing indebtedness and general corporate purposes. The Offering closed on July 30, 2025.
     
    Pursuant to the Subscription Agreement, the Company has agreed to file a resale registration statement on Form F-3 (or other available form) (the “Registration Statement”) providing for the resale by the purchasers of the Common Shares, the Warrant Shares, the Pre-Funded Shares and the Finder’s Warrant Shares (as defined below) within thirty (30) calendar days of the Closing Date. The Company also agreed to use commercially reasonable efforts to cause such Registration Statement to become effective as soon as practicable, but in no event later than the date, which shall be either: (i) in the event that the U.S. Securities and Exchange Commission does not review the Registration Statement, sixty (60) calendar days after the Closing Date, or (ii) in the event that the U.S. Securities and Exchange Commission reviews the Registration Statement, ninety (90) days after the Closing Date.
     
    The foregoing summaries of the Subscription Agreements, the Warrants and the Pre-Funded Warrants do not purport to be complete and are qualified in their entirety by reference to the Form of Subscription Agreement (Non-US Investors), Form of Subscription Agreement (US Investors), Form of Common Warrant and Form of Pre-Funded Warrant, which are attached as Exhibits 99.1, 99.2, 99.3, and 99.4, respectively, to this Report of Foreign Private Issuer on Form 6-K and are incorporated herein by reference.
     

     
    Advisory Agreement
     
    In connection with the Offering, on July 31, 2025, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Pure Equity Ltd. (“Pure Equity”), pursuant to which Pure Equity provided the Company with consulting services related to the Offering. In consideration of the consulting services, the Company issued to Pure Equity a warrant (the “Finder’s Warrant”) to purchase up to 140,000 common shares of the Company (the “Finder’s Warrant Shares”). In addition, pursuant to the Consulting Agreement, Pure Equity shall be entitled to a one-time cash payment of $260,000 plus applicable taxes.
     
    The Finder’s Warrant has an exercise price of US$2.50 per Finder’s Warrant Share, became exercisable immediately upon issuance and for a period of sixty (60) months following its issuance. The Finder’s Warrant and the Finder’s Warrant Share may not be traded for a period of four (4) months, unless permitted under applicable securities legislation.
     
    The foregoing summaries of the Advisory Agreement and the Finder’s Warrant do not purport to be complete and are qualified in their entirety by reference to the Advisory Agreement and the Form of Finder’s Warrants, which are attached as Exhibits 99.5 and 99.6, respectively, to this Report of Foreign Private Issuer on Form 6-K and are incorporated herein by reference.

    The securities described herein have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.
     
    This Report of Foreign Private Issuer on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
     
    Press Release
     
    On July 31, 2025, the Company issued a press release titled: “IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million”. A copy of this press release is furnished herewith as Exhibit 99.7.
     
    Incorporation by Reference
     
    This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-288346) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.


     
    EXHIBIT INDEX
     
    Exhibit No.
     
    99.1
    Form of Subscription Agreement (Non-US Investors)
    99.2
    Form of Subscription Agreement (US Investors)
    99.3
    Form of Common Warrant
    99.4
    Form of Pre-Funded Warrant
    99.5
    Advisory Agreement, dated July 31, 2025, by and between the Company and Pure Equity
    99.6
    Form of Finder’s Warrant
    99.7
    Press Release, dated July 31, 2025, titled “IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million”



    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
    IM CANNABIS CORP.
     
    (Registrant)
     
     
     
    Date: July 31, 2025
    By:
    /s/ Oren Shuster
     
    Name:   
    Oren Shuster
     
    Title:
    Chief Executive Officer and Director


    Get the next $IMCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 5:03:53 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form F-3 filed by IM Cannabis Corp.

    F-3 - IM Cannabis Corp. (0001792030) (Filer)

    8/13/25 4:02:13 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    8/12/25 8:15:25 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Second Quarter 2025 Financial Results

    IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

    8/12/25 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

    TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

    8/4/25 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

    10/10/23 7:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

    Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

    1/13/22 8:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care